Similar names can hide important chemical, product and regulatory differences. Online references to melanotan I, melanotan II and afamelanotide are often compressed into a choice between tanning products. That framing overlooks the fact that evidence and authorization attach to a specific medicine, formulation and use.

The approved product has a defined purpose

Scenesse contains afamelanotide and is an implant indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. Its FDA labeling describes professional administration and safety monitoring. It is not a general approval for retail tanning peptides or all products using related names. FDA Scenesse prescribing information

Melanotan II is a different compound. Australia's TGA recently tested seized nasal products bearing that name and found inconsistent amounts between bottles. The regulator's warning demonstrates a product-quality problem as well as the absence of an approved tanning indication in that jurisdiction. TGA laboratory findings on melanotan II nasal products

Compare the claim with the actual evidence

Before interpreting a study, confirm the exact molecule, formulation and clinical question. A finding involving one melanocortin-active compound cannot establish the same effect for a related compound. A change in pigmentation is not the same outcome as reduced phototoxic pain, and neither should be casually described as protection from every form of ultraviolet injury.

The distinction also applies to safety. A product used under a specialist's supervision in a defined disease population is not equivalent to an unverified product used for appearance. Differences in exposure, follow-up and manufacturing can change the risks being evaluated.

AXON's comparison should therefore explain boundaries instead of selecting a preferred tanning agent. The evidence reviewed here supports a precise description of Scenesse's labeled role and a warning against extrapolating that role to other products. No comparative cosmetic-use trial establishing a safe choice between melanotan I and II was verified for this draft. Dermatology and regulatory review remain necessary before publication.